aluates Reports

$ 0.0

Automative

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-13C13917

Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2023

BUY CHAPTERS

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Research Report 2025

Code: QYRE-Auto-13C13917

Report

September 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Merck

Allergan plc

Santen Pharmaceutical

GlaxoSmithKline Pharmaceuticals

Pfizer Inc

Acucela Inc

Valent Pharmaceuticals

IVERIC

Macular Degeneration (AMD) and Other Retinal Diseases Market

The global market for Macular Degeneration (AMD) and Other Retinal Diseases was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Macular degeneration (AMD) and other retinal diseases are mainly related to long-term and chronic light damage in macular area, choroidal vascular sclerosis, and aging of retinal pigment epithelial cells, often including Lucentis, Eylea, Avastin and other brands.

North American market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Macular Degeneration (AMD) and Other Retinal Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Macular Degeneration (AMD) and Other Retinal Diseases in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Macular Degeneration (AMD) and Other Retinal Diseases include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical, GlaxoSmithKline Pharmaceuticals, Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Macular Degeneration (AMD) and Other Retinal Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Macular Degeneration (AMD) and Other Retinal Diseases.

The Macular Degeneration (AMD) and Other Retinal Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Macular Degeneration (AMD) and Other Retinal Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Macular Degeneration (AMD) and Other Retinal Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Macular Degeneration (AMD) and Other Retinal Diseases Market Report

Report Metric	Details
Report Name	Macular Degeneration (AMD) and Other Retinal Diseases Market
Segment by Type	Macular Degeneration Diabetic Macular Edema Diabetic Retinopathy(DR) Retinal Vein Occlusion Wet Age-Related Macular Degeneration (wAMD) Dry Age-Related Macular Degeneration (dAMD) Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical, GlaxoSmithKline Pharmaceuticals, Pfizer, Acucela, Valent Pharmaceuticals, IVERIC
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macular Degeneration (AMD) and Other Retinal Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Macular Degeneration (AMD) and Other Retinal Diseases Market report?

Ans: The main players in the Macular Degeneration (AMD) and Other Retinal Diseases Market are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma, Merck, Allergan, Santen Pharmaceutical, GlaxoSmithKline Pharmaceuticals, Pfizer, Acucela, Valent Pharmaceuticals, IVERIC

What are the Application segmentation covered in the Macular Degeneration (AMD) and Other Retinal Diseases Market report?

Ans: The Applications covered in the Macular Degeneration (AMD) and Other Retinal Diseases Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Macular Degeneration (AMD) and Other Retinal Diseases Market report?

Ans: The Types covered in the Macular Degeneration (AMD) and Other Retinal Diseases Market report are Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy(DR), Retinal Vein Occlusion, Wet Age-Related Macular Degeneration (wAMD), Dry Age-Related Macular Degeneration (dAMD), Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Macular Degeneration

1.2.3 Diabetic Macular Edema

1.2.4 Diabetic Retinopathy(DR)

1.2.5 Retinal Vein Occlusion

1.2.6 Wet Age-Related Macular Degeneration (wAMD)

1.2.7 Dry Age-Related Macular Degeneration (dAMD)

1.2.8 Other

1.3 Market by Application

1.3.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Perspective (2020-2031)

2.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Growth Trends by Region

2.2.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Region (2020-2025)

2.2.3 Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2026-2031)

2.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics

2.3.1 Macular Degeneration (AMD) and Other Retinal Diseases Industry Trends

2.3.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers

2.3.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges

2.3.4 Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue

3.1.1 Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Revenue (2020-2025)

3.1.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Players (2020-2025)

3.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Macular Degeneration (AMD) and Other Retinal Diseases Revenue

3.4 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio

3.4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2024

3.5 Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases Head office and Area Served

3.6 Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases, Product and Application

3.7 Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Type

4.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Type (2020-2025)

4.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2026-2031)

5 Macular Degeneration (AMD) and Other Retinal Diseases Breakdown Data by Application

5.1 Global Macular Degeneration (AMD) and Other Retinal Diseases Historic Market Size by Application (2020-2025)

5.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2020-2031)

6.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025)

6.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2020-2031)

7.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025)

7.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2020-2031)

8.2 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2020-2025)

8.4 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2020-2031)

9.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025)

9.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size (2020-2031)

10.2 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025)

10.4 Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Regeneron Pharmaceuticals

11.1.1 Regeneron Pharmaceuticals Company Details

11.1.2 Regeneron Pharmaceuticals Business Overview

11.1.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.1.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.1.5 Regeneron Pharmaceuticals Recent Development

11.2 Bayer HealthCare

11.2.1 Bayer HealthCare Company Details

11.2.2 Bayer HealthCare Business Overview

11.2.3 Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.2.4 Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.2.5 Bayer HealthCare Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.3.4 Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.3.5 Novartis Recent Development

11.4 Roche

11.4.1 Roche Company Details

11.4.2 Roche Business Overview

11.4.3 Roche Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.4.4 Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.4.5 Roche Recent Development

11.5 Kanghong Pharma

11.5.1 Kanghong Pharma Company Details

11.5.2 Kanghong Pharma Business Overview

11.5.3 Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.5.4 Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.5.5 Kanghong Pharma Recent Development

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.6.4 Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.6.5 Merck Recent Development

11.7 Allergan

11.7.1 Allergan Company Details

11.7.2 Allergan Business Overview

11.7.3 Allergan Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.7.4 Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.7.5 Allergan Recent Development

11.8 Santen Pharmaceutical

11.8.1 Santen Pharmaceutical Company Details

11.8.2 Santen Pharmaceutical Business Overview

11.8.3 Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.8.4 Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.8.5 Santen Pharmaceutical Recent Development

11.9 GlaxoSmithKline Pharmaceuticals

11.9.1 GlaxoSmithKline Pharmaceuticals Company Details

11.9.2 GlaxoSmithKline Pharmaceuticals Business Overview

11.9.3 GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.9.4 GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.9.5 GlaxoSmithKline Pharmaceuticals Recent Development

11.10 Pfizer

11.10.1 Pfizer Company Details

11.10.2 Pfizer Business Overview

11.10.3 Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.10.4 Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.10.5 Pfizer Recent Development

11.11 Acucela

11.11.1 Acucela Company Details

11.11.2 Acucela Business Overview

11.11.3 Acucela Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.11.4 Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.11.5 Acucela Recent Development

11.12 Valent Pharmaceuticals

11.12.1 Valent Pharmaceuticals Company Details

11.12.2 Valent Pharmaceuticals Business Overview

11.12.3 Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.12.4 Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.12.5 Valent Pharmaceuticals Recent Development

11.13 IVERIC

11.13.1 IVERIC Company Details

11.13.2 IVERIC Business Overview

11.13.3 IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Introduction

11.13.4 IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

11.13.5 IVERIC Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Merck

Allergan plc

Santen Pharmaceutical

GlaxoSmithKline Pharmaceuticals

Pfizer Inc

Acucela Inc

Valent Pharmaceuticals

IVERIC

List of Tables

Table 1. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Macular Degeneration

Table 3. Key Players of Diabetic Macular Edema

Table 4. Key Players of Diabetic Retinopathy(DR)

Table 5. Key Players of Retinal Vein Occlusion

Table 6. Key Players of Wet Age-Related Macular Degeneration (wAMD)

Table 7. Key Players of Dry Age-Related Macular Degeneration (dAMD)

Table 8. Key Players of Other

Table 9. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2020-2025)

Table 13. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2026-2031)

Table 15. Macular Degeneration (AMD) and Other Retinal Diseases Market Trends

Table 16. Macular Degeneration (AMD) and Other Retinal Diseases Market Drivers

Table 17. Macular Degeneration (AMD) and Other Retinal Diseases Market Challenges

Table 18. Macular Degeneration (AMD) and Other Retinal Diseases Market Restraints

Table 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players (2020-2025)

Table 21. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2024)

Table 22. Ranking of Global Top Macular Degeneration (AMD) and Other Retinal Diseases Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases, Headquarters and Area Served

Table 25. Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases, Product and Application

Table 26. Global Key Players of Macular Degeneration (AMD) and Other Retinal Diseases, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2020-2025)

Table 30. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Type (2026-2031)

Table 32. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2020-2025)

Table 34. Global Macular Degeneration (AMD) and Other Retinal Diseases Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Macular Degeneration (AMD) and Other Retinal Diseases Revenue Market Share by Application (2026-2031)

Table 36. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Country (2026-2031) & (US$ Million)

Table 51. Regeneron Pharmaceuticals Company Details

Table 52. Regeneron Pharmaceuticals Business Overview

Table 53. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 54. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 55. Regeneron Pharmaceuticals Recent Development

Table 56. Bayer HealthCare Company Details

Table 57. Bayer HealthCare Business Overview

Table 58. Bayer HealthCare Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 59. Bayer HealthCare Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 60. Bayer HealthCare Recent Development

Table 61. Novartis Company Details

Table 62. Novartis Business Overview

Table 63. Novartis Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 64. Novartis Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 65. Novartis Recent Development

Table 66. Roche Company Details

Table 67. Roche Business Overview

Table 68. Roche Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 69. Roche Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 70. Roche Recent Development

Table 71. Kanghong Pharma Company Details

Table 72. Kanghong Pharma Business Overview

Table 73. Kanghong Pharma Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 74. Kanghong Pharma Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 75. Kanghong Pharma Recent Development

Table 76. Merck Company Details

Table 77. Merck Business Overview

Table 78. Merck Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 79. Merck Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 80. Merck Recent Development

Table 81. Allergan Company Details

Table 82. Allergan Business Overview

Table 83. Allergan Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 84. Allergan Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 85. Allergan Recent Development

Table 86. Santen Pharmaceutical Company Details

Table 87. Santen Pharmaceutical Business Overview

Table 88. Santen Pharmaceutical Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 89. Santen Pharmaceutical Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 90. Santen Pharmaceutical Recent Development

Table 91. GlaxoSmithKline Pharmaceuticals Company Details

Table 92. GlaxoSmithKline Pharmaceuticals Business Overview

Table 93. GlaxoSmithKline Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 94. GlaxoSmithKline Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 95. GlaxoSmithKline Pharmaceuticals Recent Development

Table 96. Pfizer Company Details

Table 97. Pfizer Business Overview

Table 98. Pfizer Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 99. Pfizer Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 100. Pfizer Recent Development

Table 101. Acucela Company Details

Table 102. Acucela Business Overview

Table 103. Acucela Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 104. Acucela Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 105. Acucela Recent Development

Table 106. Valent Pharmaceuticals Company Details

Table 107. Valent Pharmaceuticals Business Overview

Table 108. Valent Pharmaceuticals Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 109. Valent Pharmaceuticals Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 110. Valent Pharmaceuticals Recent Development

Table 111. IVERIC Company Details

Table 112. IVERIC Business Overview

Table 113. IVERIC Macular Degeneration (AMD) and Other Retinal Diseases Product

Table 114. IVERIC Revenue in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025) & (US$ Million)

Table 115. IVERIC Recent Development

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

Table 119. Authors List of This Report

List of Figures

Figure 1. Macular Degeneration (AMD) and Other Retinal Diseases Picture

Figure 2. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Type: 2024 VS 2031

Figure 4. Macular Degeneration Features

Figure 5. Diabetic Macular Edema Features

Figure 6. Diabetic Retinopathy(DR) Features

Figure 7. Retinal Vein Occlusion Features

Figure 8. Wet Age-Related Macular Degeneration (wAMD) Features

Figure 9. Dry Age-Related Macular Degeneration (dAMD) Features

Figure 10. Other Features

Figure 11. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Application: 2024 VS 2031

Figure 13. Hospital Case Studies

Figure 14. Clinic Case Studies

Figure 15. Other Case Studies

Figure 16. Macular Degeneration (AMD) and Other Retinal Diseases Report Years Considered

Figure 17. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region: 2024 VS 2031

Figure 20. Global Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Players in 2024

Figure 21. Global Top Macular Degeneration (AMD) and Other Retinal Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Macular Degeneration (AMD) and Other Retinal Diseases as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Other Retinal Diseases Revenue in 2024

Figure 23. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2020-2031)

Figure 25. United States Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2020-2031)

Figure 29. Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Region (2020-2031)

Figure 37. China Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2020-2031)

Figure 45. Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Share by Country (2020-2031)

Figure 49. Turkey Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 53. Bayer HealthCare Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 54. Novartis Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 55. Roche Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 56. Kanghong Pharma Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 57. Merck Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 58. Allergan Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 59. Santen Pharmaceutical Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 60. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 61. Pfizer Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 62. Acucela Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 63. Valent Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 64. IVERIC Revenue Growth Rate in Macular Degeneration (AMD) and Other Retinal Diseases Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Macular Degeneration Treatment Market Research Report 2024

Global Ophthalmology for Age related Macular Degeneration Diseases Market Research Report 2024

Global Macular Edema and Macular Degeneration Market Research Report 2025

Global Ophthalmology Disorders Drug Market Insights Forecast to 2030

Global Retinal Disorders Treatment Market Research Report 2024

Global Wet Macular Degeneration Market Research Report 2024

Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024

Retinal Degenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions